This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Adding the measurement that post #60 says would settle it.
Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain elsewhere. Others repackage standard compounds. Verifying what you are buying requires careful documentation review.
Where I would look next, rather than where I would stop.
Acknowledging rather than arguing. The reasoning holds as far as I can follow it.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
The step people skip is the one I have spelled out.
Colour in a lyophilised cake is worth noting for the less common compounds specifically, because some of them are genuinely not white and a member expecting white will report a problem that is not one.
The conclusion is tentative; the arithmetic underneath it is not.
The arithmetic in post #64 is right; the assumption feeding it is the part to check.
Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.
Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds with supplier pages.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Nothing above should be read as advice about what anyone else should do.
Post #66 put the caveat in the right place and I want to underline it.
Nicotinamide adenine dinucleotide preparations are not peptides at all and the certificate conventions are completely different. Reading one as though it were a peptide certificate produces confusion in both directions.
The disagreement above is smaller than it looks once the terms are fixed.
Useful. I had the fact and not the reason, which turns out to be the important half.
On analysis: unusual or modified sequences are exactly where a default reversed-phase method is least likely to be appropriate. A supplier that runs everything on one gradient will produce a flattering result for something.
Caveat: everything above assumes the paperwork is what it says it is.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
I have separated what I observed from what I concluded, which does not always happen.
Post #70 is the version of this I will quote in future. One addition.
Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.
That is the version I would defend. It is not the version I started with.
Nicotinamide adenine dinucleotide preparations are not peptides at all and the certificate conventions are completely different. Reading one as though it were a peptide certificate produces confusion in both directions.
Following, with nothing to contribute beyond having asked the same thing elsewhere.
I had written a reply contradicting post #73 and deleted it. Here is what survived.
Solubility varies far more across this subcategory than within the incretins. A compound that needs a specific diluent or a specific pH is not being difficult; it has a solubility profile and the supplier should state it.
Reporting the observation and leaving the explanation open deliberately.
Confirming post #73 from a second method, which matters more than confirming it from a second person.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
A qualification I should have led with rather than closed on.
The tanning compounds carry a specific practical point that is not pharmacological: any change to a pigmented lesion is a reason to see a clinician, and that is not a matter of opinion or of dose.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
I would treat the number as indicative rather than as a measurement.
Grateful for the specificity. Vague answers to this question are what sent me looking.
On analysis: unusual or modified sequences are exactly where a default reversed-phase method is least likely to be appropriate. A supplier that runs everything on one gradient will produce a flattering result for something.
Post #80 and I disagree about the size of the effect, not about the direction.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Narrowing post #82, because the general version has more than one answer.
Solubility varies far more across this subcategory than within the incretins. A compound that needs a specific diluent or a specific pH is not being difficult; it has a solubility profile and the supplier should state it.
I checked the source rather than the summary, and they differ.
Where a compound has a legitimate pharmaceutical form somewhere in the world, the labelling for that form is usually the single most useful document available and is almost never consulted here.
Someone will know this better than I do and I hope they say so.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
The reasoning is more useful than the number, which is why I have shown it.
Right — I had this wrong and I am glad to have read it before it mattered.
Post #85 answers the question as asked. The question underneath it is different.
Solubility varies far more across this subcategory than within the incretins. A compound that needs a specific diluent or a specific pH is not being difficult; it has a solubility profile and the supplier should state it.
I read post #84 twice before replying, because I had assumed the opposite.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Anyone with a larger sample, please post it.
Research use only, not approved for human use, and in this subcategory the compounds vary enormously in how much is known about them. It is worth establishing which end of that range a specific compound sits at before anything else.
A single observation, in a thread that deserves better than single observations.